clinical trial · NCT03250338
Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML
Arog Pharmaceuticals, Inc.·phase3·completed·n = 106
Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating MutationsCrenolanibCytarabineMitoxantronePlacebo Oral TabletFludarabineIdarubicinG-CSF
brief summary
This is a randomized, multi-center, double-blind, placebo-controlled study designed to evaluate the efficacy of crenolanib administered following salvage chemotherapy, consolidation chemotherapy, post bone marrow transplantation and as maintenance in relapsed/refractory AML subjects with FLT3 activating mutation.
started
Aug 16, 2018
primary completion
Apr 3, 2026
completion
Apr 3, 2026
last updated
Apr 9, 2026
official title
Phase III Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of the Addition of Crenolanib to Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Subjects ≤ 75 Years of Age With Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol